Orexin pathway in Parkinson's disease: a review

Mol Biol Rep. 2023 Jul;50(7):6107-6120. doi: 10.1007/s11033-023-08459-5. Epub 2023 May 8.

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease (NDD) caused by dopaminergic neuron degeneration in the substantia nigra (SN). Orexin is a neuropeptide that plays a role in the pathogenesis of PD. Orexin has neuroprotective properties in dopaminergic neurons. In PD neuropathology, there is also degeneration of orexinergic neurons in the hypothalamus, in addition to dopaminergic neurons. However, the loss of orexinergic neurons in PD began after the degeneration of dopaminergic neurons. Reduced activity of orexinergic neurons has been linked to developing and progressing motor and non-motor symptoms in PD. In addition, the dysregulation of the orexin pathway is linked to the development of sleep disorders. The hypothalamic orexin pathway regulates various aspects of PD neuropathology at the cellular, subcellular, and molecular levels. Finally, non-motor symptoms, particularly insomnia and disturbed sleep, promote neuroinflammation and the accumulation of neurotoxic proteins as a result of defects in autophagy, endoplasmic reticulum (ER) stress, and the glymphatic system. As a result, this review aimed to highlight the potential role of orexin in PD neuropathology.

Keywords: Neurodegenerative disease; Neuropathology; Neuropeptide; Orexin; Parkinson’s disease.

Publication types

  • Review

MeSH terms

  • Dopaminergic Neurons / metabolism
  • Humans
  • Neurodegenerative Diseases* / metabolism
  • Neuropeptides* / metabolism
  • Orexins / genetics
  • Orexins / metabolism
  • Parkinson Disease* / genetics
  • Parkinson Disease* / metabolism

Substances

  • Orexins
  • Neuropeptides